Erratum to: Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases (EMBO Molecular Medicine, (2016), 8, 11, (1265-1288), 10.15252/emmm.201505889);Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases

EMBO Molecular Medicine

Volumn 8, Issue 11, 2016, Pages 1265-1288

  Regula, Jörg T ^a   Lundh von Leithner, Peter ^b   Foxton, Richard ^b,c   Barathi, Veluchamy A ^d,e   Cheung, Chui Ming Gemmy ^d   Bo Tun, Sai Bo ^d   Wey, Yeo Sia ^d   Iwata, Daiju ^b   Dostalek, Miroslav ^c   Moelleken, Jörg ^a   Stubenrauch, Kay G ^a   Nogoceke, Everson ^c   Widmer, Gabriella ^c   Strassburger, Pamela ^c   Koss, Michael J ^f,g   Klein, Christian ^c   Shima, David T ^b   Hartmann, Guido ^c  

^a ROCHE INNOVATION CENTER MUNICH   (Germany)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d SINGAPORE EYE RESEARCH INSTITUTE   (Singapore)

^e DUKE NUS MEDICAL SCHOOL   (Singapore)

^f GOETHE UNIVERSITY   (Germany)

^g UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

age related macular degeneration; angiogenesis; angiopoietin 2; Fc receptor; vascular endothelial growth factor

Indexed keywords

ANGIOPOIETIN 2; CD16 ANTIGEN; MONOCLONAL ANTIBODY; RG 7716; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN A ANTIBODY; VASCULOTROPIN ANTIBODY; IMMUNOLOGIC FACTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CROSS REACTION; DRUG CLEARANCE; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; EYE DISEASE; HUMAN; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN TARGETING; RETINA EDEMA; RETINA VASCULITIS; SUBRETINAL NEOVASCULARIZATION; UPREGULATION; VITREOUS BODY; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; EYE DISEASES; ISOLATION AND PURIFICATION; MACACA FASCICULARIS; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PRECLINICAL STUDY; TREATMENT OUTCOME;

ANGIOPOIETIN-2; ANIMALS; ANTIBODIES, MONOCLONAL; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; EYE DISEASES; IMMUNOLOGIC FACTORS; MACACA FASCICULARIS; NEOVASCULARIZATION, PATHOLOGIC; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84994100942     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.15252/emmm.201707895     Document Type: Erratum

References (60)

1. Aguilar E, Dorrell MI, Friedlander D, Jacobson RA, Johnson A, Marchetti V, Moreno SK, Ritter MR, Friedlander M (2008) Chapter 6 Ocular models of angiogenesis. Methods Enzymol 444: 115–158
2. Asahara T, Chen D, Takahashi T, Fujikawa K, Kearney M, Magner M, Yancopoulos GD, Isner JM (1998) Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res 83: 233–240
3. Augustin HG, Koh GY, Thurston G, Alitalo K (2009) Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 10: 165–177
4. Barnett JM, Yanni SE, Penn JS (2010) The development of the rat model of retinopathy of prematurity. Doc Ophthalmol 120: 3–12
5. Barton WA, Tzvetkova-Robev D, Miranda EP, Kolev MV, Rajashankar KR, Himanen JP, Nikolov DB (2006) Crystal structures of the Tie2 receptor ectodomain and the angiopoietin-2-Tie2 complex. Nat Struct Mol Biol 13: 524–532
6. Benest AV, Kruse K, Savant S, Thomas M, Laib AM, Loos EK, Fiedler U, Augustin HG (2013) Angiopoietin-2 is critical for cytokine-induced vascular leakage. PLoS One 8: e70459
7. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 116: 57–65
8. Cahoon JM, Rai RR, Carroll LS, Uehara H, Zhang X, O'Neil CL, Medina RJ, Das SK, Muddana SK, Olson PR et al (2015) Intravitreal AAV2.COMP-Ang1 Prevents Neurovascular Degeneration in a Murine Model of Diabetic Retinopathy. Diabetes 64: 4247–4259
9. Cai J, Kehoe O, Smith GM, Hykin P, Boulton ME (2008) The angiopoietin/Tie-2 system regulates pericyte survival and recruitment in diabetic retinopathy. Invest Ophthalmol Vis Sci 49: 2163–2171
10. Campochiaro PA (2013) Ocular neovascularization. J Mol Med (Berl) 91: 311–321
11. Chang TS, Bressler NM, Fine JT, Dolan CM, Ward J, Klesert TR (2007) Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol 125: 1460–1469
12. Dumont DJ, Gradwohl G, Fong GH, Puri MC, Gertsenstein M, Auerbach A, Breitman ML (1994) Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev 8: 1897–1909
13. Fiedler U, Reiss Y, Scharpfenecker M, Grunow V, Koidl S, Thurston G, Gale NW, Witzenrath M, Rosseau S, Suttorp N et al (2006) Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med 12: 235–239
14. Funatsu H, Yamashita H, Ikeda T, Mimura T, Eguchi S, Hori S (2003) Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 110: 1690–1696
15. Hammes HP, Feng Y, Pfister F, Brownlee M (2011) Diabetic retinopathy: targeting vasoregression. Diabetes 60: 9–16
16. Hartnett ME, Martiniuk D, Byfield G, Geisen P, Zeng G, Bautch VL (2008) Neutralizing VEGF decreases tortuosity and alters endothelial cell division orientation in arterioles and veins in a rat model of ROP: relevance to plus disease. Invest Ophthalmol Vis Sci 49: 3107–3114
17. Ho AC, Busbee BG, Regillo CD, Wieland MR, Van Everen SA, Li Z, Rubio RG, Lai P (2014) Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 121: 2181–2192
18. Jo N, Mailhos C, Ju M, Cheung E, Bradley J, Nishijima K, Robinson GS, Adamis AP, Shima DT (2006) Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol 168: 2036–2053
19. Julien S, Biesemeier A, Taubitz T, Schraermeyer U (2014) Different effects of intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues of monkey eyes. Br J Ophthalmol 98: 813–825
20. Kabat EA, Wu TT (1991) Identical V region amino acid sequences and segments of sequences in antibodies of different specificities: relative contributions of VH and VL genes, minigenes, and complementarity-determining regions to binding of antibody-combining sites. J Immunol 147: 1709–1719
21. Kienast Y, Klein C, Scheuer W, Raemsch R, Lorenzon E, Bernicke D, Herting F, Yu S, The HH, Martarello L et al (2013) Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy. Clin Cancer Res 19: 6730–6740
22. Kim H, Robinson SB, Csaky KG (2009) FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye. Mol Vis 15: 2803–2812
23. Koss MJ, Pfister M, Koch FH (2011) Inflammatory and angiogenic protein detection in the human vitreous: cytometric bead assay. J Ophthalmol 2011: 459251
24. Koss MJ, Hoffmann J, Nguyen N, Pfister M, Mischak H, Mullen W, Husi H, Rejdak R, Koch F, Jankowski J et al (2014) Proteomics of vitreous humor of patients with exudative age-related macular degeneration. PLoS One 9: e96895
25. Kumpers P, Gueler F, David S, Slyke PV, Dumont DJ, Park JK, Bockmeyer CL, Parikh SM, Pavenstadt H, Haller H et al (2011) The synthetic tie2 agonist peptide vasculotide protects against vascular leakage and reduces mortality in murine abdominal sepsis. Crit Care 15: R261
26. Lambert NG, Zhang X, Rai RR, Uehara H, Choi S, Carroll LS, Das SK, Cahoon JM, Kirk BH, Bentley BM et al (2016) Subretinal AAV2.COMP-Ang1 suppresses choroidal neovascularization and vascular endothelial growth factor in a murine model of age-related macular degeneration. Exp Eye Res 145: 248–257
27. Lee J, Park DY, Park I, Chang W, Nakaoka Y, Komuro I, Yoo OJ, Koh GY (2014) Angiopoietin-1 suppresses choroidal neovascularization and vascular leakage. Invest Ophthalmol Vis Sci 55: 2191–2199
28. Liang WC, Wu X, Peale FV, Lee CV, Meng YG, Gutierrez J, Fu L, Malik AK, Gerber HP, Ferrara N et al (2006) Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem 281: 951–961
29. Loukovaara S, Robciuc A, Holopainen JM, Lehti K, Pessi T, Liinamaa J, Kukkonen KT, Jauhiainen M, Koli K, Keski-Oja J et al (2013) Ang-2 upregulation correlates with increased levels of MMP-9, VEGF, EPO and TGFbeta1 in diabetic eyes undergoing vitrectomy. Acta Ophthalmol 91: 531–539
30. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N et al (1997) Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277: 55–60
31. Marneros AG (2016) Increased VEGF-A promotes multiple distinct aging diseases of the eye through shared pathomechanisms. EMBO Mol Med 8: 208–231
32. Menden H, Welak S, Cossette S, Ramchandran R, Sampath V (2015) Lipopolysaccharide (LPS)-mediated angiopoietin-2-dependent autocrine angiogenesis is regulated by NADPH oxidase 2 (Nox2) in human pulmonary microvascular endothelial cells. J Biol Chem 290: 5449–5461
33. Meyer T, Robles-Carrillo L, Robson T, Langer F, Desai H, Davila M, Amaya M, Francis JL, Amirkhosravi A (2009) Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice. J Thromb Haemost 7: 171–181
34. Nagai N, Lundh von Leithner P, Izumi-Nagai K, Hosking B, Chang B, Hurd R, Adamson P, Adamis AP, Foxton RH, Ng YS et al (2014) Spontaneous CNV in a novel mutant mouse is associated with early VEGF-A-driven angiogenesis and late-stage focal edema, neural cell loss, and dysfunction. Invest Ophthalmol Vis Sci 55: 3709–3719
35. Nambu H, Nambu R, Oshima Y, Hackett SF, Okoye G, Wiegand S, Yancopoulos G, Zack DJ, Campochiaro PA (2004) Angiopoietin 1 inhibits ocular neovascularization and breakdown of the blood-retinal barrier. Gene Ther 11: 865–873
36. Nambu H, Umeda N, Kachi S, Oshima Y, Akiyama H, Nambu R, Campochiaro PA (2005) Angiopoietin 1 prevents retinal detachment in an aggressive model of proliferative retinopathy, but has no effect on established neovascularization. J Cell Physiol 204: 227–235
37. Nishijima K, Ng YS, Zhong L, Bradley J, Schubert W, Jo N, Akita J, Samuelsson SJ, Robinson GS, Adamis AP et al (2007) Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 171: 53–67
38. Noma H, Funatsu H, Mimura T, Harino S, Hori S (2010) Aqueous humor levels of vasoactive molecules correlate with vitreous levels and macular edema in central retinal vein occlusion. Eur J Ophthalmol 20: 402–409
39. Oshima Y, Deering T, Oshima S, Nambu H, Reddy PS, Kaleko M, Connelly S, Hackett SF, Campochiaro PA (2004) Angiopoietin-2 enhances retinal vessel sensitivity to vascular endothelial growth factor. J Cell Physiol 199: 412–417
40. Oshima Y, Oshima S, Nambu H, Kachi S, Takahashi K, Umeda N, Shen J, Dong A, Apte RS, Duh E et al (2005) Different effects of angiopoietin-2 in different vascular beds: new vessels are most sensitive. Faseb J 19: 963–965
41. Park SW, Yun JH, Kim JH, Kim KW, Cho CH, Kim JH (2014) Angiopoietin 2 induces pericyte apoptosis via alpha3beta1 integrin signaling in diabetic retinopathy. Diabetes 63: 3057–3068
42. Patsch C, Challet-Meylan L, Thoma EC, Urich E, Heckel T, O'Sullivan JF, Grainger SJ, Kapp FG, Sun L, Christensen K et al (2015) Generation of vascular endothelial and smooth muscle cells from human pluripotent stem cells. Nat Cell Biol 17: 994–1003
43. Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, Hartnett ME (2008) Vascular endothelial growth factor in eye disease. Prog Retin Eye Res 27: 331–371
44. Puri MC, Rossant J, Alitalo K, Bernstein A, Partanen J (1995) The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells. EMBO J 14: 5884–5891
45. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, MARINA Study Group (2006a) Ranibizumab for neovascular age-related macular degeneration. New Engl J Med 355: 1419–1431
46. Rosenfeld PJ, Rich RM, Lalwani GA (2006b) Ranibizumab: phase III clinical trial results. Ophthalmol Clin North Am 19: 361–372
47. Saharinen P, Eklund L, Miettinen J, Wirkkala R, Anisimov A, Winderlich M, Nottebaum A, Vestweber D, Deutsch D, Koh GY et al (2008) Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts. Nat Cell Biol 10: 527–537
48. Saharinen P, Bry M, Alitalo K (2010) How do angiopoietins Tie in with vascular endothelial growth factors? Curr Opin Hematol 17: 198–205
49. Sato TN, Tozawa Y, Deutsch U, Wolburg-Buchholz K, Fujiwara Y, Gendron-Maguire M, Gridley T, Wolburg H, Risau W, Qin Y (1995) Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 376: 70–74
50. Schaefer W, Regula JT, Bahner M, Schanzer J, Croasdale R, Durr H, Gassner C, Georges G, Kettenberger H, Imhof-Jung S et al (2011) Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci USA 108: 11187–11192
51. Schlothauer T, Rueger P, Stracke JO, Hertenberger H, Fingas F, Kling L, Emrich T, Drabner G, Seeber S, Auer J et al (2013) Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies. mAbs 5: 576–586
52. Stubenrauch K, Wessels U, Essig U, Kowalewsky F, Vogel R, Heinrich J (2013) Characterization of murine anti-human Fab antibodies for use in an immunoassay for generic quantification of human Fab fragments in non-human serum samples including cynomolgus monkey samples. J Pharm Biomed Anal 72: 208–215
53. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN, Yancopoulos GD (1996) Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87: 1171–1180
54. Thurston G, Rudge JS, Ioffe E, Zhou H, Ross L, Croll SD, Glazer N, Holash J, McDonald DM, Yancopoulos GD (2000) Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 6: 460–463
55. Wang H, Hartnett ME (2016) Regulation of signaling events involved in the pathophysiology of neovascular AMD. Mol Vis 22: 189–202
56. Watanabe D, Suzuma K, Suzuma I, Ohashi H, Ojima T, Kurimoto M, Murakami T, Kimura T, Takagi H (2005) Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Am J Ophthalmol 139: 476–481
57. World Health Organization (WHO) (2014) Visual impairment and blindness 2010. Fact Sheet N°282
58. Wu FT, Lee CR, Bogdanovic E, Prodeus A, Gariepy J, Kerbel RS (2015) Vasculotide reduces endothelial permeability and tumor cell extravasation in the absence of binding to or agonistic activation of Tie2. EMBO Mol Med 7: 770–787
59. Yu X, Seegar TC, Dalton AC, Tzvetkova-Robev D, Goldgur Y, Rajashankar KR, Nikolov DB, Barton WA (2013) Structural basis for angiopoietin-1-mediated signaling initiation. Proc Natl Acad Sci USA 110: 7205–7210
60. Ziegler T, Horstkotte J, Schwab C, Pfetsch V, Weinmann K, Dietzel S, Rohwedder I, Hinkel R, Gross L, Lee S et al (2013) Angiopoietin 2 mediates microvascular and hemodynamic alterations in sepsis. J Clin Invest 123: 3436–3445